Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $80.60 Average PT from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have received a consensus recommendation of “Hold” from the seven analysts that are covering the firm, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $80.60.

A number of equities analysts recently issued reports on the company. Jefferies Financial Group lowered their price target on Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th.

Prestige Consumer Healthcare Stock Down 1.1%

Prestige Consumer Healthcare stock opened at $67.20 on Wednesday. Prestige Consumer Healthcare has a 1-year low of $57.25 and a 1-year high of $90.04. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The stock has a market cap of $3.18 billion, a PE ratio of 17.78, a P/E/G ratio of 2.14 and a beta of 0.41. The stock’s fifty day moving average is $65.85 and its two-hundred day moving average is $63.59.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The business had revenue of $283.44 million for the quarter, compared to analyst estimates of $286.93 million. During the same period in the prior year, the company posted $1.22 earnings per share. The company’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, sell-side analysts expect that Prestige Consumer Healthcare will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the transaction, the vice president owned 41,048 shares in the company, valued at $2,706,294.64. This represents a 2.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.40% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently made changes to their positions in PBH. Bank of Montreal Can increased its position in Prestige Consumer Healthcare by 2.0% during the second quarter. Bank of Montreal Can now owns 9,351 shares of the company’s stock worth $747,000 after buying an additional 182 shares during the period. Lido Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 5.4% in the fourth quarter. Lido Advisors LLC now owns 3,778 shares of the company’s stock valued at $235,000 after acquiring an additional 192 shares during the period. Profund Advisors LLC boosted its holdings in shares of Prestige Consumer Healthcare by 3.2% in the third quarter. Profund Advisors LLC now owns 6,770 shares of the company’s stock valued at $422,000 after acquiring an additional 207 shares during the period. Cerity Partners LLC grew its position in shares of Prestige Consumer Healthcare by 5.9% during the second quarter. Cerity Partners LLC now owns 3,884 shares of the company’s stock worth $310,000 after acquiring an additional 218 shares during the last quarter. Finally, UMB Bank n.a. grew its position in shares of Prestige Consumer Healthcare by 110.1% during the fourth quarter. UMB Bank n.a. now owns 418 shares of the company’s stock worth $26,000 after acquiring an additional 219 shares during the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).